This company has been marked as potentially delisted and may not be actively trading. Jounce Therapeutics (JNCE) Short Interest Ratio & Short Volume Add Compare Share Share Short Interest Stock AnalysisBuy This Stock Jounce Therapeutics Short Interest DataJounce Therapeutics (JNCE) has a short interest of 2.02 million shares, representing 4.60% of the float (the number of shares available for trading by the public). This marks a -11.40% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.8, indicating that it would take 0.8 days of the average trading volume of 2.46 million shares to cover all short positions.Current Short Interest2,020,000 sharesPrevious Short Interest2,280,000 sharesChange Vs. Previous Month-11.40%Dollar Volume Sold Short$3.88 millionShort Interest Ratio0.8 Days to CoverLast Record DateApril 15, 2023Outstanding Shares52,630,000 sharesFloat Size43,940,000 sharesShort Percent of Float4.60%Today's Trading Volume169,314 sharesAverage Trading Volume2,457,142 sharesToday's Volume Vs. Average7% Short Selling Jounce Therapeutics? Sign up to receive the latest short interest report for Jounce Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartJNCE Short Interest Over TimeJNCE Days to Cover Over TimeJNCE Percentage of Float Shorted Over Time Jounce Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20232,020,000 shares $3.88 million -11.4%4.6%0.8 $1.92 3/31/20232,280,000 shares $4.22 million -28.3%5.2%0.9 $1.85 3/15/20233,180,000 shares $4.74 million -23.7%7.2%1.1 $1.49 2/28/20234,170,000 shares $4.67 million +202.2%9.6%1.7 $1.12 2/15/20231,380,000 shares $1.55 million +3.0%3.2%0.6 $1.12 1/31/20231,340,000 shares $1.57 million -15.2%3.4%0.9 $1.17 1/15/20231,580,000 shares $1.94 million -46.3%4.0%1 $1.23 12/30/20222,940,000 shares $3.26 million +208.6%7.4%2 $1.11 12/15/2022952,600 shares $677.11 thousand -15.0%2.4%1.8 $0.71 11/30/20221,120,000 shares $985.60 thousand -17.0%2.8%3.3 $0.88 Get the Latest News and Ratings for JNCE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/20221,350,000 shares $1.36 million -8.2%3.4%4.3 $1.01 10/31/20221,470,000 shares $3.20 million -5.2%3.9%5.5 $2.18 10/15/20221,550,000 shares $3.05 million -22.5%4.1%5.3 $1.97 9/30/20222,000,000 shares $4.68 million +1.0%5.9%7.8 $2.34 9/15/20221,980,000 shares $6.16 million -3.4%5.9%7.6 $3.11 8/31/20222,050,000 shares $7.50 million -5.5%6.1%7.3 $3.66 8/15/20222,170,000 shares $10.57 million +1.9%6.4%7.5 $4.87 7/31/20222,130,000 shares $6.54 million -4.5%7.0%6.8 $3.07 7/15/20222,230,000 shares $7.63 million +8.3%7.4%7 $3.42 6/30/20222,060,000 shares $6.24 million +0.5%6.8%6 $3.03 6/15/20222,050,000 shares $6.01 million +5.7%6.8%5.2 $2.93 5/31/20221,940,000 shares $7.51 million +19.8%6.4%5.1 $3.87 5/15/20221,620,000 shares $7.06 million +4.5%5.3%3.9 $4.36 4/30/20221,550,000 shares $8.22 million +4.7%5.4%3.8 $5.30 4/15/20221,480,000 shares $10.03 million +1.4%4.6%3.7 $6.78 3/31/20221,460,000 shares $9.91 million -0.7%4.6%3.9 $6.79 3/15/20221,470,000 shares $10.13 million +1.4%4.6%4.4 $6.89 2/28/20221,450,000 shares $10.82 million +31.8%4.6%4.4 $7.46 2/15/20221,100,000 shares $8.84 million -6.8%3.5%3.4 $8.04 1/31/20221,180,000 shares $8.83 million +7.3%3.6%3 $7.48 1/15/20221,100,000 shares $6.91 million -0.9%3.3%2.7 $6.28 12/31/20211,110,000 shares $9.27 million +6.7%3.3%2.7 $8.35 12/15/20211,040,000 shares $7.78 million +20.5%3.1%2.4 $7.48 11/30/2021862,800 shares $6.62 million -2.8%2.6%1.7 $7.67 11/15/2021887,500 shares $7.68 million -38.4%2.7%1.8 $8.65 10/29/20211,440,000 shares $12.64 million -8.3%4.4%3.2 $8.78 10/15/20211,570,000 shares $13.36 million -3.1%5.0%3.9 $8.51 9/30/20211,620,000 shares $12.04 million +27.6%5.2%4.1 $7.43 9/15/20211,270,000 shares $9.86 million -27.4%4.1%2.7 $7.76 8/31/20211,750,000 shares $10.89 million -12.9%5.6%3.7 $6.22A new rule goes live in July — and the banks are quietly cashing in (Ad)A major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.To help you get started, we're giving away a FREE Wealth Protection Guide that shows you exactly how 8/13/20212,010,000 shares $10.55 million -7.8%6.5%4.3 $5.25 7/30/20212,180,000 shares $10.99 million +3.3%7.0%4.8 $5.04 7/15/20212,110,000 shares $11.71 million +1.4%6.4%4.6 $5.55 6/30/20212,080,000 shares $14.14 million +13.7%6.3%4.5 $6.80 6/15/20211,830,000 shares $13.82 million -4.2%5.5%4.6 $7.55 5/28/20211,910,000 shares $14.99 million -8.6%6.0%5.4 $7.85 5/14/20212,090,000 shares $15.11 million +6.1%6.7%5.2 $7.23 4/30/20211,970,000 shares $18.60 million +11.3%6.4%5 $9.44 4/15/20211,770,000 shares $17.29 million +42.7%6.0%4.1 $9.77 3/31/20211,240,000 shares $12.11 million +13.8%4.5%2.3 $9.77 3/15/20211,090,000 shares $13.35 million +76.2%4.0%2 $12.25 2/26/2021618,500 shares $7.27 million -42.2%3.0%1.3 $11.76 2/12/20211,070,000 shares $12.49 million +25.5%6.4%2.3 $11.67 1/29/2021852,700 shares $10.30 million -22.5%5.1%1.8 $12.08 1/15/20211,100,000 shares $8.54 million +3.8%6.5%2.3 $7.76 12/31/20201,060,000 shares $7.07 million -22.6%6.3%3.1 $6.67 12/15/20201,370,000 shares $9.43 million No Change8.1%3.7 $6.88 11/30/20201,370,000 shares $9.96 million -4.9%8.1%2.4 $7.27 11/15/20201,440,000 shares $10.60 million +50.9%8.6%1.1 $7.36 10/30/2020954,500 shares $8.31 million +0.0%8.6%0.8 $8.71 10/15/2020954,200 shares $9.32 million -40.0%5.8%0.8 $9.77 9/30/20201,590,000 shares $12.97 million +20.5%9.6%1.3 $8.16 9/15/20201,320,000 shares $14.45 million -38.3%8.0%1.1 $10.95 8/31/20202,140,000 shares $10.36 million -1.4%13.0%2.2 $4.84 8/14/20202,170,000 shares $10.16 million -2.7%13.2%9.5 $4.68 7/31/20202,230,000 shares $10.21 million +0.9%13.5%9.1 $4.58 7/15/20202,210,000 shares $11.32 million +39.9%13.4%8.5 $5.12 JNCE Short Interest - Frequently Asked Questions What is Jounce Therapeutics' current short interest? Short interest is the volume of Jounce Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 2,020,000 shares of JNCE short. 4.60% of Jounce Therapeutics' shares are currently sold short. Learn More on Jounce Therapeutics' current short interest. What is a good short interest ratio for Jounce Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. JNCE shares currently have a short interest ratio of 1.0. Learn More on Jounce Therapeutics's short interest ratio. What is a good short interest percentage for Jounce Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.60% of Jounce Therapeutics' floating shares are currently sold short. Is Jounce Therapeutics' short interest increasing or decreasing? Jounce Therapeutics saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 2,020,000 shares, a decline of 11.4% from the previous total of 2,280,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Jounce Therapeutics' float size? Jounce Therapeutics currently has issued a total of 52,630,000 shares. Some of Jounce Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Jounce Therapeutics currently has a public float of 43,940,000 shares. How does Jounce Therapeutics' short interest compare to its competitors? 4.60% of Jounce Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Jounce Therapeutics: Inhibikase Therapeutics, Inc. (4.93%), Protalix BioTherapeutics, Inc. (4.74%), Achilles Therapeutics plc (1.26%), ZIVO Bioscience, Inc. (1.77%), bluebird bio, Inc. (2.91%), Cyclo Therapeutics, Inc. (3.55%), Finch Therapeutics Group, Inc. (0.01%), NKGen Biotech, Inc. (1.16%), AlloVir, Inc. (2.56%), Calidi Biotherapeutics, Inc. (3.78%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.69 billion), Occidental Petroleum Corporation ($3.22 billion), Coinbase Global, Inc. ($2.54 billion), T. Rowe Price Group, Inc. ($2.33 billion), Paramount Global ($2.10 billion), Verisk Analytics, Inc. ($2.03 billion), Etsy, Inc. ($1.67 billion), Old Dominion Freight Line, Inc. ($1.62 billion), CarMax, Inc. ($1.60 billion), and Extra Space Storage Inc ($1.60 billion). View all of the most shorted stocks. What does it mean to sell short Jounce Therapeutics stock? Short selling JNCE is an investing strategy that aims to generate trading profit from Jounce Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Jounce Therapeutics? A short squeeze for Jounce Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of JNCE, which in turn drives the price of the stock up even further. How often is Jounce Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including JNCE, twice per month. The most recent reporting period available is April, 15 2023. More Short Interest Resources from MarketBeat Related Companies IKT Short Squeeze PLX Short Squeeze ACHL Short Squeeze ZIVO Short Squeeze BLUE Short Squeeze CYTH Short Squeeze FNCH Short Squeeze NKGN Short Squeeze ALVR Short Squeeze CLDI Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:JNCE) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn extra $1,000 per month?A little-known Title 15 provision could let you collect instant payouts — $100 to $1,000 — directly from your ...TradeSmith | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jounce Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jounce Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.